HHS Revamps Dementia Plan, Drops 2025 Treatment Goal

HHS Secretary Robert F. Kennedy Jr. unveiled an updated national dementia strategy on October 22 at Broward Health Medical Center in Fort Lauderdale, Florida. This revision replaces the previous six objectives with four new ones, emphasizing prevention and early detection.

A Shift in Focus: Prevention Over Treatment

A significant change is the removal of a key deadline from earlier plans, initially introduced in 2012, which aimed to prevent and effectively treat Alzheimer’s and related dementias by 2025. This goal has been replaced with a broader objective: reducing dementia risk throughout life.

The impact on families is substantial. The strategy estimates that 7.4 million Americans will have dementia in 2026, with projections reaching nearly 13.8 million by 2060. In 2025, over 12 million unpaid caregivers provided support, and costs for healthcare, long-term care, and hospice for those aged 65 and above are expected to hit $409 billion this year.

The four new goals are: reducing dementia risk across all life stages, accelerating research for prevention and treatment, enhancing care from diagnosis onwards, and strengthening support for patients and families. The plan now includes various forms of dementia, such as Lewy body, frontotemporal, and vascular types, reflecting public input, according to HHS.

CMS Administrator Dr. Mehmet Oz highlighted the “unacceptable” rise in dementia care costs and emphasized the importance of caregiver support and lifestyle interventions.

Funding and Next Steps

Some initiatives are already in motion. The FDA has launched the Alzheimer’s Prevention Accelerator, a new neuroscience program targeting clinical trials to prevent or delay the disease. ARPA-H has allocated up to $48.8 million for new projects on early detection and intervention, bringing its total Alzheimer’s-related investments to $155.3 million.

CMS plans to test the effectiveness of lifestyle interventions not covered by original Medicare in slowing cognitive decline through the MAHA Raise model. The update outlines priority activities for 2027 but avoids setting specific national targets, such as reducing dementia cases by a certain percentage. HHS will track progress and report findings in the 2027 Update.

While the science of risk reduction is promising, it is still evolving. The Lancet Commission identified 14 modifiable risk factors in 2024, suggesting that up to 45% of dementia cases could theoretically be prevented or delayed. This estimate assumes these factors directly cause dementia and can be eliminated, which remains unproven for each factor.

Untreated hearing loss and high midlife LDL cholesterol each contribute to about 7% of the estimated risk. Other factors include high blood pressure, diabetes, smoking, physical inactivity, depression, social isolation, and untreated vision loss. Most evidence comes from observational studies, indicating correlations rather than causation.

HHS acknowledges the limitations in its plan. A 2017 federal review found no strong evidence for any preventive intervention. A National Academies report from the same year deemed the evidence insufficient for a public health campaign but noted promising signs for cognitive training, blood pressure management, and increased physical activity. NIH has commissioned an updated review from the National Academies, expected to conclude by 2029.

Recent trials offer cautious optimism. The U.S. POINTER trial showed that a structured lifestyle program improved cognitive scores in high-risk older adults over two years. A 20-year follow-up of the ACTIVE study revealed that older adults receiving speed-of-processing training and booster sessions had a 25% lower dementia diagnosis rate compared to those without training. However, no single intervention guarantees protection.

Disparities in Risk and Diagnosis

Age remains the primary risk factor, with symptoms typically appearing after 60 in over 90% of cases. The plan highlights racial and ethnic disparities: Black Americans are twice as likely, and Hispanic Americans 1.5 times more likely, to develop Alzheimer’s or related dementias compared to white Americans.

These groups often experience delayed diagnoses and limited access to specialized care. The plan advocates for targeted outreach and culturally sensitive resources, though specific programs are not detailed in the current update.

Current Support Options for Families and Caregivers

Medicare’s GUIDE Model offers dementia care coordination and caregiver support through participating providers, with CMS planning to expand enrollment. Local Area Agencies on Aging can connect families with respite care and other community-based support services.

The FDA-cleared PrecivityAD2 blood test is available for adults 40 and older experiencing cognitive symptoms, though it is not intended as general screening. People without symptoms should consult a clinician before pursuing any testing.

The Alzheimer’s Association provides national and state-level data along with caregiving resources. A planned federal research effort will test the p-tau217 blood marker in approximately 6,000 participants within the NIH All of Us program to study broader applications.

Early Detection and Caregiver Support

The plan’s effectiveness will be assessed in the 2027 Update. Until then, it serves as a directional strategy with new funding, rather than a guarantee of new treatments or coverage.